Zealand Pharma Unveils Metabolic Frontier 2030 Strategy with OTR Therapeutics Partnership
核心洞察
Zealand Pharma announced its Metabolic Frontier 2030 strategy targeting five launches and more than ten clinical pipeline programs by 2030, positioning itself as a leader in obesity (搜索) and metabolic health.
The company entered a multi-program strategic collaboration with OTR Therapeutics (搜索) worth up to $2.5 billion to develop oral small-molecule therapeutics for metabolic diseases (搜索).
Zealand Pharma will establish a new research site in Boston combining its 25-year peptide expertise with AI-driven drug discovery and advanced automation.
Zealand Pharma has unveiled its comprehensive Metabolic Frontier 2030 strategy, aiming to establish itself as a generational biotech leader in obesity (搜索) and metabolic health through strategic partnerships, accelerated drug development, and expanded research capabilities. The Copenhagen-based biotechnology company announced its ambitious plan during a Capital Markets Day in London, outlining targets for five launches and a robust clinical pipeline of more than ten programs by 2030.
Strategic Partnership with OTR Therapeutics
Central to Zealand Pharma's strategy is a multi-program strategic collaboration and license agreement with OTR Therapeutics (搜索) to develop novel therapeutics for metabolic diseases (搜索). The partnership combines Zealand Pharma's expertise in obesity (搜索) and metabolic health with OTR Therapeutics' proprietary oral small-molecule platform and drug discovery capabilities.
Under the agreement terms, OTR Therapeutics (搜索) will receive an initial upfront payment of $20 million, potentially increasing to $30 million under certain pre-agreed conditions. The company is eligible for potential preclinical, development, regulatory, and commercial milestone payments totaling up to approximately $2.5 billion, with the majority representing commercial milestones, plus tiered single-digit royalties on worldwide net sales.
"The multi-program collaboration will expand our metabolic health pipeline into oral small-molecule therapeutics for targets where we have deep biological expertise, complementing our strong peptide R&D platform," said Utpal Singh, Chief Scientific Officer of Zealand Pharma.
Expanded Research Capabilities
Zealand Pharma plans to establish a new research site in Boston to combine its more than 25-year peptide heritage with AI-driven drug discovery, advanced automation, and next-generation molecule creation. This expansion will leverage advanced computational methods and partnerships to accelerate the drug discovery process and expand the company's molecule-making toolbox.
The collaboration structure designates OTR Therapeutics (搜索) to leverage its proprietary discovery platform to lead and conduct research and preclinical development, while Zealand Pharma will assume responsibility for clinical development, regulatory submissions, and commercialization worldwide.
Clinical Pipeline and Upcoming Catalysts
The company anticipates a catalyst-rich 2026 with multiple clinical readouts, including Phase 2 data with petrelintide in Q1 2026 and Phase 3 obesity (搜索) data with survodutide throughout 2026. Zealand Pharma's existing pipeline includes more than ten invented drug candidates that have entered clinical development, with two products having reached the market and three candidates currently in late-stage development.
"Today marks a pivotal moment for Zealand Pharma as we unveil our aim to build a generational biotech company that will fundamentally transform how we treat obesity (搜索) and metabolic disease," said Adam Steensberg, Chief Executive Officer of Zealand Pharma. "We are redefining weight management for a new era - moving beyond the Weight loss Olympics toward solutions that support the everyday needs, aspirations, and overall well-being of people living with overweight (搜索), obesity, and metabolic imbalance (搜索)."
Industry-Leading Development Timeline
The Metabolic Frontier 2030 strategy emphasizes achieving industry-leading cycle times from idea to clinic. By leveraging unrivaled peptide expertise, strengthened organization, and expanded global research capabilities, Zealand Pharma aims to accelerate its drug discovery process while maintaining scientific rigor and quality standards.
Zhui Chen, Founder and Chief Executive Officer of OTR Therapeutics (搜索), expressed enthusiasm about the partnership: "This collaboration represents a strong endorsement of our proprietary platform and strategic vision, and our proven ability to drive innovation and deliver quality and speed in execution."
The strategic approach, combined with five anticipated launches from the existing pipeline and the company's robust financial foundation, positions Zealand Pharma to achieve leadership in metabolic health while addressing some of the greatest healthcare challenges of the current era.